Clinical Trials Logo

Relapsed Small Cell Lung Cancer clinical trials

View clinical trials related to Relapsed Small Cell Lung Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04610658 Terminated - Clinical trials for Small-cell Lung Cancer

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Start date: November 23, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, phase I/II trial to determine the Maximum Tolerated Dose (MTD), Recommended Phase II Dose (RP2D), and the safety and efficacy of the combination of nivolumab-ipilimumab plus lurbinectedin in patients with relapsed/recurrent small cell lung cancer after progression with first-line, platinum-based chemotherapy

NCT ID: NCT03406715 Terminated - Lung Cancer Clinical Trials

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects (good and bad) immunotherapy treatment using the p53 vaccine (Ad.p53-DC) in combination with Nivolumab and Ipilimumab has on small cell lung cancer. Immunotherapy is a cancer therapy that uses the body's immune system to fight cancer cells. This study can be divided into three different phases: initial Induction Immunotherapy, Maintenance Immunotherapy and Retreatment.